Navigation Links
SyntheMed To Present at the AdvaMed 2008 MedTech Conference
Date:9/18/2008

ISELIN, N.J., Sept. 18 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today that it was selected to present at the AdvaMed 2008 MedTech conference being held in Washington, D.C. on September 21-24, 2008. Robert P. Hickey, President and CEO of SyntheMed, is scheduled to present on Wednesday, September 24, at 9:30 a.m. Mr. Hickey's PowerPoint presentation may be viewed at http://www.synthemed.com for thirty days after the presentation.

The purpose of the AdvaMed 2008 MedTech conference is to provide the opportunity for companies in the life sciences sector to present to an elite audience of potential investors, strategic partners and business collaborators. The selection of presenting companies is based on such criteria as: stage of product development, partnering opportunities, potential for licensing technology, intellectual property, timing of next capital raise, and overall appeal to the audience.

About AdvaMed

AdvaMed is the world's largest medical technology trade association representing over 1,600 medical technology innovators, manufacturers of medical devices, diagnostic products and medical information systems.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products, and other surgical implants. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
2. SyntheMed Files Universal Shelf Registration
3. SyntheMed to Present at the Acumen BioFin Conference
4. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
5. eResearchTechnology, Inc. to Present at the UBS Global Life Sciences Conference on September 23rd, 2008
6. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
7. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference
9. BioVex to Present at the UBS Global Life Sciences Conference
10. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
11. CryoLife to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):